Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

585.70INR
1:06pm IST
Change (% chg)

Rs1.10 (+0.19%)
Prev Close
Rs584.60
Open
Rs584.25
Day's High
Rs592.00
Day's Low
Rs583.65
Volume
885,989
Avg. Vol
1,700,942
52-wk High
Rs663.40
52-wk Low
Rs480.20

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.76 30.95 32.74
EPS (TTM): 13.38 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances

* CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO Source text: http://bit.ly/2GsCYiw Further company coverage:

26 Mar 2018

BRIEF-India's Cipla Says Unit Launches Authorized Generic Version Of Aloxi In U.S.

* SAYS ‍CO'S UNIT LAUNCHES AUTHORIZED GENERIC VERSION OF ALOXI IN U.S. Source text - http://bit.ly/2pEclNR Further company coverage:

26 Mar 2018

BRIEF-Medrx says drug development and sale contract change

* Says it enters into a license contract with Cipla Ltd's wholly owned unit Cipla Technologies, LLC, instead of with Cipla Ltd's wholly owned unit Cipla USA Inc preciously, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis, due to Cipla group' s reorganization

23 Mar 2018

BUZZ-India's Cipla shares fall; U.S. FDA found deficiencies at Goa unit - report

** Shares of pharmaceutical company Cipla Ltd fall as much as 6.6 pct to 522.90 rupees, lowest since June 6

20 Mar 2018

BRIEF-Cipla's Goa Unit FDA Inspection Finds Lab Records Deficient - TV

* CIPLA LTD GOA UNIT'S U.S. FDA INSPECTION FINDS THAT LAB RECORDS DEFICIENT, RECORDS DON'T INCLUDE COMPLETE TESTING DATA - TV Source text - http://bit.ly/2u1xLt3 Further company coverage:

20 Mar 2018

Sensex snaps seven-session losing streak, rises nearly 1 percent

Indian shares rose nearly 1 percent on Thursday, snapping seven sessions of fall, as market heavyweights such as Infosys Ltd and Housing Development Finance Corp helped the indexes end their longest spell of losses since September.

08 Feb 2018

Indian shares gain over 1 pct after 7 days of falls

Feb 8 Indian shares rose more than 1 percent on Thursday after seven consecutive sessions of declines, as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.

08 Feb 2018

BUZZ-India's Cipla surges after third-quarter results

** Shares of Cipla Ltd surge as much as 6.85 pct to 608.2 rupees, in their biggest intraday pct gain since Nov 2016

08 Feb 2018

Cipla third-quarter profit rises, but below estimates

Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

07 Feb 2018

UPDATE 1-India's Cipla Q3 profit rises, but below estimates

Feb 7 Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

07 Feb 2018

Earnings vs. Estimates